Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 51

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 51
---
 under Section 4(a)(2) of the Securities Act and
Rule 506 of Regulation D promulgated thereunder since, among other things, the transactions did not involve a public offering and the
securities were acquired for investment purposes only and not with a view to or for sale in connection with any distribution thereof.

Additionally, since January 2022, we have granted
share options and RSU’s to employees, directors, consultants and service providers under our Executive Stock Option and Restricted
Share Unit Plans. There are currently an aggregate of 81,772 stock options and RSU’s outstanding, with exercise prices ranging from
$23.40 to $642.03 per share.

Item 8. Exhibits and Financial Statement Schedules.

(a) Exhibits.See the Exhibit Index attached
to this registration statement, which is incorporated by reference herein.

(b) Financial Statement Schedules. Schedules
not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes thereto.

<div align='center'>II-2</div>

Item 9. Undertakings.

| (a) | The undersigned Registrant hereby undertakes: |

| (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |

| i. | To include any prospectus required by section 10(a)(3) of the Securities Act; |

| ii. | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; |

| iii. | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |

| (2) |